Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).
Alice S. Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center—James, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).
A lot of the newer targeted therapies are exciting, but not curative, says Mims. The field needs to do a better job of curing patients rather than extending their survival, Mims adds.
To that end, the Beat AML Master Trial, led by the Leukemia and Lymphoma Society, is looking at an older population of patients with AML, mostly those who are 60 years and older. These patients will undergo molecular testing, and results are received within 1 week. Patients who have dominant clones are put on particular therapies. If the patient doesn’t have targetable mutations, they are given investigational therapy. That trial has shown some exciting results and, hopefully, will lead to new therapies in that patient population, concludes Mims.